Legal Status of Peptides in Competitive Sports

Which rules apply

If you compete in a sport that tests under the World Anti-Doping Code, WADA's Prohibited List decides which peptides you can use. National agencies such as USADA apply it to Olympic and Paralympic sport and to other bodies that adopt the Code. As of October 2026, the 2026 List is in force. WADA has also published the 2027 List, which takes effect on January 1, 2027. College sport (NCAA) and many professional leagues run their own programs with their own lists, which this page doesn't cover.

A few Code rules shape everything below. Athletes are strictly liable for any prohibited substance found in their sample, so fault and intent come in only when the sanction is set. A substance can be prohibited even if the List never names it, because most sections give examples rather than complete lists. And the section a substance sits in decides whether it's "Specified" or "non-Specified", which changes the default ban.

For the short version, see our overview of peptides and anti-doping rules. Untested federations have their own page on the legal side of peptides in bodybuilding, and drug law outside sport is covered under legal and ethical considerations.

The 2026 List, section by section

S0: non-approved substances

S0 catches any pharmacological substance that no other section covers and that has "no current approval by any governmental regulatory health authority for human therapeutic use." WADA's examples include experimental or discontinued drugs and veterinary-only products. Everything in S0 is prohibited at all times, and every S0 substance is a Specified Substance.

BPC-157 is named in S0. WADA added it to the 2022 List, the first time it had named any substance as an example in this section, and it's still named in the 2026 List. The published 2027 List keeps it and adds "peptides" to the S0 examples. USADA's advisory on the 2027 List warns that a peptide missing from the List, or from its Global DRO lookup, may still be prohibited.

Melanotan II isn't named anywhere on the 2026 List. It isn't approved in any country, so our reading of the S0 definition is that it falls there by default. Two newly approved medicines are less clear (see below).

S2.2.3: growth hormone and its fragments

The 2026 List names AOD-9604 and hGH 176-191 as growth hormone fragments under S2.2.3, not S4 or S0 as older guides (and an earlier version of this page) said. Everything in S2 is non-Specified.

S2.2.4: growth hormone releasing factors

This section names most of the compounds sold as GH-releasing peptides:

• GHRH analogues: CJC-1293 and CJC-1295, plus sermorelin and tesamorelin
• Growth hormone secretagogues: ibutamoren (MK-677) and ipamorelin, among others
• GHRPs: GHRP-1 through GHRP-6, plus examorelin (hexarelin) and alexamorelin

Tesamorelin is an approved prescription medicine (Egrifta) for HIV-associated lipodystrophy. That doesn't change its status. S2 bans the substance itself, whereas S0 depends on whether a substance is approved.

S2.3: growth factors

S2.3 names IGF-1 and its analogues, which covers IGF-1 LR3, along with mechano growth factors and "Thymosin-β4 and its derivatives e.g. TB-500." So as of the 2026 List, TB-500 is named in S2.3, not S0 as this page used to say. The section ends with a catch-all for other growth factor modulators that affect tendon or ligament protein synthesis or regenerative capacity, which is close to how healing peptides are marketed.

S4: hormone and metabolic modulators

MOTS-c is named in S4.4.1 among AMPK activators. Myostatin-blocking agents such as ACE-031 and follistatin sit in S4.3, and insulins in S4.4.2. Substances in S4.3 and S4.4 are non-Specified. Melanotan II isn't in S4, despite older claims that its appetite effects put it there.

Not prohibited, or unclear

Semaglutide and tirzepatide aren't prohibited. They're in WADA's Monitoring Program for 2026 and again for 2027, so labs track their use but no sanction applies. Bremelanotide (PT-141, approved as Vyleesi) and elamipretide (SS-31, approved as Forzinity in 2025) aren't named. Because both now have regulatory approval, the S0 definition no longer clearly applies, and we couldn't confirm their status as of October 2026. An athlete's national anti-doping organization is the right place to ask.

Quick reference (2026 List)

Why "it's only for an injury" doesn't help

A common forum argument is that a peptide used to heal an injury isn't doping. Under the Code, that argument doesn't decide whether a violation happened. WADA adds a substance when it meets two of its three listing criteria, and the two that most obviously fit an unapproved healing peptide are potential performance enhancement and health risk. Returning to full training sooner after a tendon injury is a performance benefit in WADA's terms. The S2.3 wording about tendon and ligament repair shows the List was written with that in mind.

Intent can still change the length of a ban (see below), but it doesn't change guilt. WADA's own guidance adds that S2 peptides are prohibited by any route, so a cosmetic cream containing a prohibited growth factor counts too.

Testing and detection

Anti-doping labs have built methods for the peptides people ask about most. A WADA-funded project at Ghent University (approved in 2013) mapped how TB-500 breaks down in human liver preparations. The team made reference standards for three metabolites and shared them with other doping control labs; urine detection limits were 50-500 pg/mL. For BPC-157, a 2023 study described a urine method for the peptide and five of its metabolites with detection limits of 0.01-0.11 ng/mL, well under the 2 ng/mL minimum WADA sets for peptide testing. Both studies worked with lab incubations and spiked samples rather than dosed volunteers. How long a test stays positive after someone uses these peptides is still unknown.

A positive test isn't the only route to a ban. The Code treats use or possession as violations in their own right, and they can be proven with other evidence; USADA calls these non-analytical cases. Samples that test negative can be stored and reanalysed later, and an anti-doping organization has 10 years from the date of a violation to bring a case.

Therapeutic use exemptions

A therapeutic use exemption (TUE) lets an athlete use a prohibited substance for a medical need. Under WADA's international TUE standard, as USADA's 2026 policy restates it, the substance must be prescribed for a diagnosed condition supported by clinical evidence. It must also be an indicated treatment with no reasonable permitted alternative, and it can't do more than return the athlete to normal health.

Unapproved peptides have trouble meeting those tests. When BPC-157 joined the List in 2022, USADA said there was "no basis for granting a TUE" because it isn't an approved therapeutic agent in any country. USADA's current BPC-157 page is slightly softer: a TUE is unlikely because permitted alternatives exist, and each application is judged case by case. An approved prescription medicine on the List, such as tesamorelin for HIV-associated lipodystrophy, is a different situation, since it has a labeled indication behind it.

Sanctions

Until December 31, 2026, sanctions follow the 2021 Code:

• Non-Specified substances (all of S2, plus S4.3 and S4.4): the default for a first violation is a 4-year ban. It drops to 2 years if the athlete proves the violation wasn't intentional.
• Specified substances (all of S0, so BPC-157): the default is 2 years, rising to 4 if the anti-doping organization proves intent.

Further reductions are possible where the athlete bears no significant fault, as with a proven contaminated product. Competitive results from the affected period are lost as well.

The 2027 Code, approved in Busan in December 2025, takes effect on January 1, 2027, alongside the 2027 List. WADA's implementation factsheet says it keeps the 4-year and 2-year defaults but adds a 3-year step in some cases where use was unrelated to sport performance. It also allows a 25% reduction for athletes who accept a charge within 20 days.

What to watch next

• The 2027 List takes effect on January 1, 2027, with "peptides" among the S0 examples. We've taken that wording from a federation-hosted copy of the List and from USADA's advisory, so check WADA's own text before relying on the exact phrasing.
• Whether WADA names elamipretide or bremelanotide now that both are approved medicines.
• Whether GLP-1 drugs ever move from monitoring onto the List. For 2027 they stay in the Monitoring Program.